Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
一项针对晚期实体恶性肿瘤患者的 I 期研究，旨在评估双重原肌球蛋白受体激酶 A 和细胞周期蛋白依赖性激酶抑制剂 PHA-848125AC 的安全性、耐受性和药代动力学。
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-011-9774-6
Weiss, Glen J; Hidalgo, Manuel; Borad, Mitesh J; Laheru, Daniel; Tibes, Raoul; Ramanathan, Ramesh K; Blaydorn, Lisa; Jameson, Gayle; Jimeno, Antonio; Isaacs, Jeffrey D; Scaburri, Angela; Pacciarini, Maria Adele; Fiorentini, Francesco; Ciomei, Marina; Von Hoff, Daniel D
